Thomas G. Ricks - 21 May 2025 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Reporting relationship: Director
Issuer ticker: SNSE
Reported as of: 21 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 May 2025, 16:30:20 UTC
Prior SEC filing: 20 May 2025
Next SEC filing: 08 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark Ballantyne, Attorney-in-Fact

Key filing fact

Thomas G. Ricks filed Form 4 for Sensei Biotherapeutics, Inc. (SNSE) on 23 May 2025.

Key facts

This page summarizes Thomas G. Ricks's Form 4 filing for Sensei Biotherapeutics, Inc. (SNSE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 May 2025, 16:30.

Change

Previous filing in this sequence was filed on 20 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001013023 Primary reporting owner

RICKS THOMAS G

Relationship: Director
Address: C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Signature date: 23 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNSE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +19,000
Change %
Price: $0.000000
Shares after: 19,000
Date: 21 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,000
Exercise price: $0.3202
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.